About Opna Bio

Opna Bio develops targeted oncology therapeutics that inhibit key regulators of immune suppression and epigenetic reprogramming, specifically through compounds like OPN-2853 and OPN-6602. Their approach aims to enhance treatment efficacy for cancer patients by addressing mechanisms that allow tumor cells to evade immune detection and promote uncontrolled growth.

```xml <problem> Many cancers evade detection and destruction by the immune system through mechanisms like immune suppression and epigenetic reprogramming. Current cancer treatments often fail to address these resistance mechanisms, leading to suboptimal efficacy and disease progression. </problem> <solution> Opna Bio develops targeted therapeutics designed to inhibit key regulators of immune suppression and epigenetic reprogramming in cancer cells. Their pipeline includes compounds like OPN-2853, a BET inhibitor, and OPN-6602, a dual inhibitor of EP300 and CBP, both of which are currently in clinical development. By targeting these master regulators, Opna Bio aims to enhance the efficacy of cancer treatments by preventing tumor cells from evading immune detection and promoting uncontrolled growth. Their approach focuses on nonmutational epigenetic reprogramming and avoiding immune destruction, addressing key hallmarks of cancer. </solution> <features> - OPN-2853: A BET inhibitor in Phase 1 clinical trials for advanced myelofibrosis, often used in combination with Ruxolitinib. - OPN-6602: A best-in-class EP300/CBP inhibitor in Phase 1 clinical trials for relapsed/refractory multiple myeloma. - OPN-FMRP: An FMRP inhibitor targeting solid tumors by addressing immune evasion. - OPN-7486: A compound in preclinical development. - OPN-9840: A compound in preclinical development. - OPN-9627: A compound in preclinical development. - Focus on epigenetic inhibitors with differentiated pharmacokinetics (PK) for improved safety and efficacy. </features> <target_audience> Opna Bio's primary target audience includes patients with hematologic malignancies such as multiple myeloma and myelofibrosis, as well as those with solid tumors. </target_audience> ```

What does Opna Bio do?

How much funding has Opna Bio raised?

Opna Bio has raised 38000000.

Funding

38000000

Employees

18 employees

Major Investors

Longitude Capital, Northpond Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Opna Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

opnabio.com 700+

Crunchbase

Funding

Estimated Funding

$20M+

Major Investors

Longitude Capital, Northpond Ventures

Team (15+)

No team information available.

Company Description

Problem

Many cancers evade detection and destruction by the immune system through mechanisms like immune suppression and epigenetic reprogramming. Current cancer treatments often fail to address these resistance mechanisms, leading to suboptimal efficacy and disease progression.

Solution

Opna Bio develops targeted therapeutics designed to inhibit key regulators of immune suppression and epigenetic reprogramming in cancer cells. Their pipeline includes compounds like OPN-2853, a BET inhibitor, and OPN-6602, a dual inhibitor of EP300 and CBP, both of which are currently in clinical development. By targeting these master regulators, Opna Bio aims to enhance the efficacy of cancer treatments by preventing tumor cells from evading immune detection and promoting uncontrolled growth. Their approach focuses on nonmutational epigenetic reprogramming and avoiding immune destruction, addressing key hallmarks of cancer.

Features

OPN-2853: A BET inhibitor in Phase 1 clinical trials for advanced myelofibrosis, often used in combination with Ruxolitinib.

OPN-6602: A best-in-class EP300/CBP inhibitor in Phase 1 clinical trials for relapsed/refractory multiple myeloma.

OPN-FMRP: An FMRP inhibitor targeting solid tumors by addressing immune evasion.

OPN-7486: A compound in preclinical development.

OPN-9840: A compound in preclinical development.

OPN-9627: A compound in preclinical development.

Focus on epigenetic inhibitors with differentiated pharmacokinetics (PK) for improved safety and efficacy.

Target Audience

Opna Bio's primary target audience includes patients with hematologic malignancies such as multiple myeloma and myelofibrosis, as well as those with solid tumors.